Bristol Myers Squibb Wins FDA Accelerated Approval for ZENBEXUS, Its First CELMoD Therapy for Multiple Myeloma
核心洞察
Bristol Myers Squibb (搜索) received FDA accelerated approval for ZENBEXUS (搜索), its first CELMoD therapy, for multiple myeloma (搜索) patients as early as first relapse.
The approval rests on Phase 3 data showing a significantly higher MRD-negative complete response rate versus the standard comparator regimen.
ZENBEXUS (搜索) is priced at $29,500 per 28-day cycle, positioning it as a new growth driver for BMS as older myeloma treatments mature.
Princeton, NJ-based Bristol Myers Squibb (BMS) has won accelerated FDA approval for ZENBEXUS (搜索), its first CELMoD therapy, making the drug available to multiple myeloma (搜索) patients as early as their first relapse. The approval is based on Phase 3 data showing a significantly higher MRD-negative complete response rate than the standard comparator regimen.
The regulatory milestone gives BMS a new growth driver in multiple myeloma (搜索) just as its older myeloma treatments mature, while simultaneously extending the company's end-to-end U.S. presence from discovery through manufacturing.
A New Option at First Relapse
ZENBEXUS (搜索) represents BMS's first CELMoD (cereblon E3 ligase modulator) therapy to reach the market. The accelerated approval pathway reflects the therapy's potential to address an unmet need in multiple myeloma (搜索), where patients who relapse after initial treatment have historically faced limited options.
The approval is supported by Phase 3 clinical data demonstrating a significantly higher MRD-negative complete response rate compared with the standard comparator regimen. Minimal residual disease (MRD)-negative complete response is an increasingly important efficacy measure in multiple myeloma (搜索), as achieving MRD negativity has been associated with improved long-term outcomes.
Commercial Positioning and Pricing
ZENBEXUS (搜索) is priced at $29,500 per 28-day cycle. The launch positions the drug as a new growth driver for BMS within its oncology portfolio, arriving at a time when the company's older myeloma treatments are maturing.
Manufacturing Expansion
In parallel with the approval, BMS is advancing its U.S. manufacturing investment with a new $2.3 billion, 600,000 square-foot campus in Houston, Texas. The facility is part of the company's $40 billion U.S. manufacturing commitment and is expected to create nearly 500 permanent positions once operational.
The Houston investment builds on BMS's deep Greater Philadelphia-area footprint, anchored by its Lawrenceville R&D headquarters and Princeton Pike commercial campus, extending the company's end-to-end U.S. presence from discovery through manufacturing.